Cancer marker and therapeutic agent for cancer
AssigneesHisamitsu Pharmaceutical Co., Inc., Chiba-Prefecture
InventorsYasutoshi TATSUMI, Akira NAKAGAWARA
Life of this patent
Estimating the term…
Abstract
A novel cancer marker is provided. A method for detecting cancer using a level of BMCC1 gene expression as an indication is provided, in which the cancer is selected from the group consisting of prostate cancer, lung cancer, gastric cancer, bladder cancer, and uterine cancer.
Claims11
A method for detecting cancer using a level of BMCC1 gene expression as an indication, wherein the cancer is selected from the group consisting of prostate cancer, lung cancer, gastric cancer, bladder cancer, and uterine cancer.
A siRNA targeting DD3, wherein the siRNA is double-stranded siRNA comprising a pair of oligonucleotides of any one of (a) to (d) as described below;
- (a) an oligonucleotide comprising a sequence described in SEQ ID NO:
- 11 and an oligonucleotide comprising a sequence described in SEQ ID NO:
- 12;
- (b) an oligonucleotide comprising a sequence described in SEQ ID NO:
- 13 and an oligonucleotide comprising a sequence described in SEQ ID NO:
- 14;
- (c) an oligonucleotide comprising a sequence described in SEQ ID NO:
- 15 and an oligonucleotide comprising a sequence described in SEQ ID NO:
- 16;
- and
- (d) an oligonucleotide comprising a sequence described in SEQ ID NO:
- 30 and an oligonucleotide comprising a sequence described in SEQ ID NO:
- 31.
Dependencies are inferred from the claim text.